BrainStorm Cell Therapeutics Inc. Enters Letter Of Intent To Begin Preclinical Primate Studies Of Stem Cell-Based Therapy For Parkinson's Disease; Testing To Begin By Year-End, With Clinical Human Trials To Follow As Soon As Possible

NEW YORK--(BUSINESS WIRE)--Sept. 12, 2006--BrainStorm Cell Therapeutics (OTCBB:BCLI), a leader in Adult Stem Cell Research, announced today that it has entered into a Letter Of Intent (LOI) with the Center for Applied Medical Research (CIMA) of the University of Navarra to conduct safety trials in primates of the Company's Parkinson's disease stem cell therapy. The team at the Movement Disorders Unit in Parkinson's Disease at the University has over 20 years experience in researching and applying new therapies to treat Parkinson's disease, and anticipates being among the first to use BrainStorm's technology to treat patients in its own University Hospital. The trials will be conducted in Pamplona, Spain, with the intention to move into human clinical trials as soon as is practically possible.

Back to news